# A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

> **NCT06826612** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 53 (estimated)

## Conditions studied

- Huntington Disease

## Interventions

- **GENETIC:** SPK-10001
- **OTHER:** Placebo Surgery Control

## Key facts

- **NCT ID:** NCT06826612
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-21
- **Primary completion:** 2035-01-12
- **Final completion:** 2035-01-12
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06826612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06826612, "A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06826612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*